EUCTR2010-021474-11-IT进行中（未招募）不适用
A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in dementia diagnostic category and diagnostic confidence after DaTSCAN imaging in subjects with an uncertain diagnosis of dementia with Lewy bodies (possible DLB) - ND
GE Healthcare Srl0 个研究点目标入组 174 人开始时间: 2010年12月24日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Male or female 55 years of age or older. (2) Mini-Mental State Examination between 10 and 26. (3) Subjects with Possible DLB as defined by the International Consensus Criteria (dementia +1 core feature or 1 or more suggestive features), who may or may not also fulfil criteria for Alzheimer’s disease (AD). (4) The subject and a legally acceptable representative (e.g., the subject’s carer) are able and willing to comply with study procedures and signed and dated informed consent is obtained from each. (5) The subject and a legally authorised representative are able to co-operate with the protocol and involvement would not adversely affect subject care, in the opinion of the investigator. (6) Women who are surgically sterile (have had documented oophorectomy and/or documented hysterectomy) or are postmenopausal (cessation of menses for more than 1 year) will be allowed to enrol in the study without a pregnancy test at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Having an established/certain clinical diagnosis of probable DLB or a non-DLB form of dementia. (2) Parkinsonism >1 year prior to onset of dementia. (3) Severe extrapyramidal symptoms (Unified Parkinson’s Disease Rating Scale, Part 3 [UPDRS-III] >30) or Parkinson’s disease dementia. (4) Known/suspected significant vascular pathology with multiple or strategic infarcts or vascular pathology in the striatum/basal ganglia as shown preferably by previous magnetic resonance imaging (MRI) or computed tomography (CT) examination. If an MRI is not clinically feasible, cerebral CT imaging within 6 months prior to baseline is also acceptable. (5) Symptoms suggestive of multiple system atrophy, corticobasal degeneration, progressive supranuclear palsy, or Huntington’s disease. (6) Persistent severe mental illness including depression, schizophrenia and schizoaffective illness. (7) Normal pressure hydrocephalus. (8) Use of any concomitant medication that is known or suspected to interact with striatal uptake through direct competition with binding of DaTSCAN to the DAT that could not be discontinued for at least 5 half-lives if the subject were to be randomized to the DaTSCAN group (these include amphetamine, benztropine, bupropion, cocaine, mazindol, methylphenidate, phentermine and sertraline). (9) Presence of moderate to severe renal or hepatic impairment. (10) Occupational exposure to radiation equal to or above 15 mSv per year. (11) History of abuse or current abuse of drugs. (12) History of alcohol abuse where period of abstinence is less than 3 years. (13) Hypersensitivity to DaTSCAN or any of its ingredients. (14) Previous inclusion in this study. (15) Female subjects who are pregnant or breast-feeding or planning a pregnancy during the course of this study or within 3 cycles of completing the study. Women of childbearing potential, have to provide a negative beta human chorionic gonadotropin (b-HCG) pregnancy test (by urine dipstick method) at screening and also prior to investigational medicinal product (IMP) administration. (16) Participation in a clinical study involving an unlicensed pharmaceutical product within 30 days prior to screening, and/or an unlicensed/licensed radiopharmaceutical within 5 radioactive half-lives prior to screening. (17) The subject has a life threatening disease state with a life expectancy of less than 1 year or history of significant medical disease, trauma, or surgical intervention that in the judgement of the investigators makes the subject unsuitable for the study. (18) The subject has already had DaTSCAN SPECT imaging or any other similar functional imaging test of the pre-synaptic and/or post-synaptic dopaminergic system (e.g. 18FDOPA PET, 123I iodobenzamide).
研究者
相似试验
进行中（未招募）
不适用
A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in clinical management after DaTSCAN imaging of subjects with clinically uncertain parkinsonism in a general neurologist setting - NDclinically uncertain parkinsonismMedDRA version: 6.1Level: PTClassification code 10034010EUCTR2005-002216-25-ITGE Healthcare Ltd e le sue filiali250
进行中（未招募）
不适用
A multicentre, randomised, open label, comparative Phase 4 trial to assess changes in clinical management after DaTSCAN™ imaging of subjects with clinically uncertain parkinsonism in a general neurologist settingThe subjects included in this trial will have clinically uncertain parkinsonism in a general neurologist setting.MedDRA version: 8.0Level: LLTClassification code 10037142EUCTR2005-002216-25-DKGE Healthcare Ltd and its affliates250
尚未招募
不适用
Study of the efficacy and safety of Tiotropium bromide,in patients with COPD.CTRI/2017/10/010024Rus Biopharm LLC
暂停
不适用
To evaluate efficacy and safety of Respiforb in patients with partly controlled asthmaCTRI/2018/09/015862PSK Pharma LLC
终止
4 期
Oestrogen cream or a simple lubricant to treat vaginal dryness in women on Arimidex treatment for breast cancerAtrophic vaginitisCancer - BreastRenal and Urogenital - Other renal and urogenital disordersBreast cancerACTRN12609000154202School of Women's and Infants' Health84